Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Carnosine regulatory status

Current status of Carnosine in the United States: Not eligible for compounding. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of Carnosine?

Regulatory: Not eligible for compoundingWADA: Not WADA prohibitedVerified: Verified Sep 29, 2026
FDA and compounding
Not an FDA approved drug. L-carnosine was nominated for the 503A bulks list, and FDA placed it in Category 3, meaning it was nominated without enough support for FDA to evaluate it. Category 3 substances do not get the enforcement discretion FDA gives Category 1 substances. As of the last verification date, carnosine was not on the 503A bulks list, and no Pharmacy Compounding Advisory Committee review of it had been identified. Whether a USP or NF monograph gives pharmacies a separate route is unconfirmed, so no compounded injectable route has been confirmed.
WADA
Not WADA prohibited
Access path
  1. Over the counter dietary supplement, no prescription needed.
  2. Beta-alanine supplements as a precursor for raising muscle carnosine.

Full Carnosine page: evidence, dosing in the literature, and sources

How has the status of Carnosine changed over time?

No dated regulatory event has been recorded for Carnosine. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Carnosine and the source of each dated event.

  1. [1]WADA Prohibited ListWADA, 2026